284 results about "Muscle atrophy" patented technology

The invention belongs to the technical field of microorganisms and fermentation engineering, and particularly relates to application of bifidobacterium longum subsp. Infantis Y46 in the anti-aging aspect. The bifidobacterium longum subsp. Infantis Y46 is obtained from excrement of infants. Animal experiments prove that living cell thalli (Y46) and thermally inactivated cell thalli (HKY46) obtained by culturing the bifidobacterium longum subsp. Infantis Y46 by using an MRS liquid culture medium containing L-cysteine hydrochloride (0.05%, v / v) can significantly reduce accumulation of lipofuscin in a host, and prolong the healthy life and life of the host. Therefore, the bifidobacterium longum subsp. Infantis Y46 is a promising probiotic and a promising metagen with an anti-aging function.

The invention discloses an application of NSUN2 in muscle injury repair. Research finds that the number of activated muscle stem cells of a CTX model mouse can be remarkably increased and proliferation of the muscle stem cells can be promoted by mediating NSUN2 overexpression through AAV, and the overexpression of the NSUN2 not only improves the activation level of the muscle stem cells, but also enhances the self-renewal capacity of the muscle stem cells; in addition, overexpression of NSUN2 also significantly increases the area of muscle fibers of CTX model mice and reduces the weight of muscle atrophy. Overexpression of the NSUN2 promotes muscle fiber repair and muscle mass recovery by promoting proliferation and activation of muscle stem cells, so that healing of muscle injury is promoted, and the NSUN2 has a treatment effect on the disease. Therefore, the invention provides a new method for the treatment of muscle injury, and a new way is possibly opened up for the treatment of other muscle-related diseases.

The invention discloses application of a bifidobacterium animalis subspecies F1-7 in preparation of a medicine for preventing or treating sarcopenia, belongs to the technical field of microorganism application, and provides application of the bifidobacterium animalis subspecies F1-7 in preparation of the medicine for preventing or treating sarcopenia. The invention relates to an application of bifidobacterium animalis subspecies F1-7 in preparation of drugs for improving bile acid metabolic function decline caused by sarcopenia. The invention relates to an application of bifidobacterium animalis subspecies F1-7 in preparation of a medicine for improving intestinal flora imbalance caused by sarcopenia. The invention finds that the bifidobacterium animalis subspecies F1-7 can effectively improve the skeletal muscle quality of mice with sarcopenia, improve the condition of tension reduction, regulate intestinal flora, promote bile acid metabolism and further relieve muscular atrophy, and enriches a probiotic library for improving sarcopenia.

The invention belongs to the technical field of microbial function development, and particularly relates to lactobacillus plantarum YD666 and application of the lactobacillus plantarum YD666 in products for slowing down muscle atrophy and osteoporosis, the lactobacillus plantarum YD666 is preserved in the China Center for Type Culture Collection with the preservation number of CCTCC No: M 2025897, a preparation method of a lactobacillus plantarum YD666 bacterial suspension is provided, and the lactobacillus plantarum YD666 bacterial suspension can be used for preparing the lactobacillus plantarum YD666 bacterial suspension with the preservation number of CCTCC No: M 2025897. According to the lactobacillus plantarum YD666 and the application of the lactobacillus plantarum YD666 bacterial suspension in preparation of products for slowing down muscle atrophy and osteoporosis, the weight index of skeletal muscles of suspended tail rats can be increased by slowing down muscle weight loss caused by weightlessness; growth of muscle fibers is promoted, and the proportion of conversion from slow muscles to fast muscles is reduced, so that a weightlessness environment is resisted; the muscle movement contraction strength of the suspended tail rats is maintained, so that the application of relieving muscle atrophy under weightlessness is achieved, and the device is suitable for astronauts, crowds lack of movement and bedridden people who suffer from long-term illness and has wide market potential and application prospects.

There is provided a method for diagnosing a subject with early onset muscle atrophy, said method comprising: obtaining a biosample from the subject; and assaying the biosample for one or more biomarkers, said one more biomarkers are taurine, proline, citrulline, trigonelline, thymidine, ornithine, glutamate, L-pyroglutamic acid, creatinine, adenine, nicotinamide, 2-methylhippuric acid, maltol, L-arginine, hypotaurine, L-glutamine, homogentisic acid, methylhistidine, oxoglutaric acid, xanthine, L-carnitine, succinate, or a combination thereof; and identifying the subject with early onset muscle atrophy on the basis of a deviation in the one or more of said one more biomarkers.

The invention discloses a bionic self-crimping material and application in the nerve field, and relates to the technical field of nano materials. The preparation method comprises the following steps: firstly, carrying out ultraviolet photopolymerization on acrylic acid and acrylic acid-N-hydroxysuccinimide, adding chitosan and glutaraldehyde to form hydrogel, and introducing epigallocatechin gallate into a chitosan-acrylic acid network. The material is rapidly and autonomously curled into a tube shape after being in contact with wet nerves, glutaraldehyde is directionally and orderly diffused by adopting a three-channel micro-fluidic chip, and the fineness is improved, so that the matching degree of nerve broken ends with different thicknesses is increased; the surface active groups of the material and the natural component chitosan cooperate to realize suture-free fixation; the plant phenol antioxidant removes free radicals at nerve injury parts; the degradation period is synchronous with natural healing of nerves, and secondary operation for taking out is not needed. The electroneurographic signals using the material are transmitted more smoothly, the target muscle atrophy degree is reduced, and the limb movement function is recovered to be close to the normal level.

The utility model discloses an orthopedic nursing traction support, which relates to the technical field of medical instruments, and comprises a bracket, an adjusting pad is arranged on one side of the bracket in a sliding and penetrating manner, the other side of the bracket is fixedly connected with a stand column, the bottom of the bracket is fixedly connected with an assembly block, and the lower end of the assembly block is provided with a first hydraulic oil cylinder. By means of the assembling block and the connecting shaft, the angle of the extension rods on the two sides is adjusted, the fixing device is suitable for patients of different body types, after the feet of the patients are fixed to the fixing base, the stability of the position of the fracture broken end can be maintained, shortening and displacement of the fracture broken end are overcome, fracture reduction is more accurate, and during follow-up rehabilitation training, the rehabilitation training efficiency is improved. The position of the sliding seat on the extension rod can be adjusted, the knee joint is driven to be bent in cooperation with rotation of the extension rod, and the provided traction force assists in functional exercise of limbs, promotes blood circulation, prevents amyotrophy and joint stiffness and accelerates recovery of limb functions.

The invention provides a self-generating electricity stimulation scoliosis orthosis, and belongs to the technical field of medical instruments. The device comprises a support, protection plates installed at the two ends of the support, a correction belt adjuster installed on the support, a correction belt connected to the correction belt adjuster, a pressure sensor arranged on the correction belt, piezoelectric material modules arranged on a chest belt, a waist belt and the correction belt respectively, and electrode slices used for being connected with the piezoelectric material modules. The correction force is monitored in real time through the pressure sensor and transmitted to the terminal, the piezoelectric material module is utilized to generate electricity for stimulation under the action of mechanical pressure, collaborative treatment of muscle atrophy and the correction force is achieved, the dual functions of accurate regulation and control of the correction force and maintenance of muscle activity are achieved, and the correction effect is improved.

Provided are compositions comprising, and methods of administering, gene therapy vectors, particularly recombinant AAV vectors encoding AUF1 proteins for expression in muscle cells for restoring or increasing muscle mass, muscle function or performance, and / or reducing or reversing muscle atrophy. The compositions and methods may be used for the treatment of subject suffering from sarcopenia, muscle degenerative disease or traumatic injury.

The invention discloses a bean dreg solid state fermentation preparation and application thereof in treating or preventing sarcopenia, and relates to the field of bean dreg processing, the bean dreg solid state fermentation preparation is obtained by taking lactobacillus paracasei LMX1 and pediococcus acidilactici IFJ1 as fermentation strains, taking bean dregs as a fermentation substrate, firstly performing solid state fermentation and then performing extraction. A myotubular atrophy model is established by inducing mouse myoblast C2C12 injury with TNF-alpha in vitro, the effect of the bean dreg solid-state fermentation preparation on C2C12 cells is explored, the influence of the bean dreg solid-state fermentation preparation on LPS-induced muscular atrophy mice is researched in vivo, and the result shows that the bean dreg solid-state fermentation preparation has potential effects of delaying senescence, promoting growth of muscular atrophy, preventing and treating muscular atrophy. The composition has the effects of preventing muscle atrophy and weakness related to aging and treating sarcopenia, and reference is provided for exploring potential application of plant active ingredients in the aspect of preventing or treating muscle functions.

The invention belongs to the field of pharmaceutical compositions, and relates to a composition for delaying muscle aging and application thereof. The composition comprises curcumin and milk-derived protein, and can help to delay the problems of muscle atrophy, muscle movement ability decline and the like caused by muscle aging. The composition has both functionality and nutrition, and shows a wide application prospect in the aspects of improving muscle functions and athletic ability.

Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.

The present invention discloses an upper limb muscle rehabilitation training device based on electrical stimulation induction, comprising: a first main body, the first main body comprising a forearm section, a wrist section, and a palm section, the forearm section and the palm section both being provided with stimulation electrodes, the forearm section being connected to the wrist section, and the wrist section being connected to the palm section; and a second main body, the second main body corresponding to the forearm section and provided with stimulation electrodes; the first main body and the second main body being hinged, and a locking mechanism being provided between the first and second main bodies, the locking mechanism being used to lock the open and closed state between the first and second main bodies. The upper limb muscle rehabilitation training device disclosed in the present invention can induce coordinated active contraction during training, enabling the hand to complete coordinated grasping and stretching movements, thereby promoting the completion of training movements, maintaining neuromuscular excitability, and preventing or delaying muscle atrophy.

The invention provides application of desulfurization vibrio in screening of drugs or functional food for preventing and treating sarcopenia. According to the application disclosed by the invention, a main intestinal flora desulfurization vibrio capable of promoting amyotrophy is firstly found, and the desulfurization vibrio can be used as a main target for screening sarcopenia and can be used for screening medicines or functional foods for preventing and treating sarcopenia. Sinopenia susceptible people are screened through abundance of desulfurization vibrio in excrement, and early discovery and targeted early intervention can be carried out; aiming at the mechanism that desulfurization vibrio in intestinal tracts promotes occurrence and development of sarcopenia, drugs or functional food for treating sarcopenia can be further screened, and then substances / new therapy for preventing and treating sarcopenia are developed.

Provided herein are codon-optimized Smad7 polynucleotides and vectors comprising codon-optimized Smad7 polynucleotides for use in increasing or prolonging Smad7 expression in a subject.

The purpose of the present invention is to provide a composition for suppressing muscle atrophy. The present invention relates to a composition for suppressing muscle atrophy, characterized by containing ergothioneine or a salt thereof as an active ingredient.

The invention features the use of an adenylate deaminase base editor to destroy the scissor acceptor site of a disease-related gene, including compositions and methods for treating genetic diseases, particularly for treating, alleviating or ameliorating the asthenic effect of amyotrophic lateral sclerosis (ALS) and spinal bulbar muscular atrophy (SBMA). Provided herein are compositions and methods for using improved new base editors (e.g., adenosine base editors) comprising a polynucleotide programmable nucleotide binding domain and a nucleobase editing domain that cooperate with a guide polynucleotide, e.g., adenosine base editors, for example, adenosine base editors, for example, adenosine base editors, for example, adenosine base editors, for example, adenosine base editors, for example, adenosine base editors. The present invention relates to a method for modifying a target gene associated with a hereditary disease or disorder, such as ALS or SBMA, by modifying the target gene using a base editor system provided herein to disrupt normal transcription of a gene associated with the hereditary disease or disorder.

The present invention relates to novel use of a cathepsin L inhibitor Z-Phe-Tyr-CHO (C26H26N2O5), wherein the cathepsin L inhibitor Z-Phe-Tyr-CHO inhibits cancer progression and cachexia and muscle damage that are caused by cancer, and thus can be effectively used for preventing, ameliorating or treating cachexia and muscle loss, while having anticancer activity.

The purpose of the present invention is to provide a composition which has high biosafety and contributes to the activation of PGC-1 [alpha]. In addition, the invention aims to provide application of the composition for activating the PGC-1 alpha and a method for activating the PGC-1 alpha. It has been found that a specific compound among natural product-derived compounds has a PGC-1 [alpha] activating effect. The present invention provides an effective and novel method which contributes to improvement of durability, muscle hypertrophy, inhibition of obesity, stress reduction, improvement of glucose metabolism function, and inhibition of muscle atrophy.

It was confirmed that probiotic metabolites of the present invention protect muscle cells and promote differentiation of muscle fibers. In addition, it was confirmed in an animal model of muscle atrophy or sarcopenia induced by dexamethasone that probiotic metabolites increased muscle mass and muscle function, inhibited expression of factors associated with muscle degradation, and increased expression of factors associated with muscle synthesis and regeneration. It was confirmed that probiotic metabolites contribute to alleviation of muscle atrophy by regulating sugar, amino acid, and fatty acid metabolism altered by dexamethasone.

This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain embodiments, the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated with muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.

The invention provides an application of GW8510 in preparation of a medicine for treating amyotrophy. Compared with the prior art, the invention provides a new application of the GW8510 in treating amyotrophy. Experimental research proves that the GW8510 administration can significantly recover the athletic ability of mice with amyotrophy, improve the cross-sectional area of the muscles of the mice and recover the activity of creatine kinase in serum of the mice, so that the phenotype of the amyotrophy of the mice and related biochemical indexes of the amyotrophy are improved; the GW8510 can be used for remarkably recovering cell amyotrophy related gene and protein expression, and improving amyotrophy phenotype through an MSTNPGC1 alpha NRF2 related pathway; the GW8510 can be used for remarkably recovering cell fibrosis and denervation related gene expression and improving fibrosis and denervation degrees in a muscle atrophy model.

The present invention belongs to the field of pharmaceutical synthesis, and specifically relates to salviphorol derivatives and their application in drugs for treating cancer cachexia. Salviphorol compounds include compounds represented by formula (X) and / or formula (Y), or pharmaceutically acceptable salts or optical isomers of the compounds represented by formula (X) and / or formula (Y). The present invention also provides a pharmaceutical composition for treating cachexia diseases, and its application in the preparation of drugs for treating cancer cachexia, including muscle atrophy caused by tumor tissues, fat reduction caused by tumor tissues, reduced appetite caused by tumor tissues, inflammatory responses caused by tumor tissues, and cancer cachexia caused by digestive tract-related cancers, liver cancer, lung cancer, and colon cancer. The present invention also provides its application in the preparation of drugs or inhibitors for treating or inhibiting muscle atrophy, drugs or inhibitors for inhibiting or alleviating adipocyte lipolysis, and drugs or inhibitors for inhibiting or alleviating weight loss or reduction.

The invention discloses a sarcopenia electromyographic signal acquisition and analysis system, and belongs to the technical field of medical detection. The system comprises an electromyographic signal acquisition module, a signal preprocessing module, a feature extraction module, an analysis and diagnosis module and a result output module which are electrically connected in sequence, the electromyographic signal acquisition module adopts a flexible dry electrode array to realize noninvasive and anti-interference acquisition; the signal preprocessing module outputs high-quality electromyographic signals through self-adaptive trapped wave, band-pass filtering and standardization processing; the feature extraction module extracts time domain, frequency domain and nonlinear multi-dimensional features; the analysis and diagnosis module is used for completing low, medium and high three-level risk assessment of sarcopenia and judgment of muscle fiber atrophy type, innervation disorder type and metabolic disorder type decline types on the basis of a deep learning model; and the result output module stores the data and generates an evaluation result. According to the invention, noninvasive, accurate and efficient screening and diagnosis of sarcopenia are realized, a scientific basis is provided for clinical intervention, and the method is suitable for various medical health scenes.

Provided are methods of treating spinal muscular atrophy (SMA) using a combination of a 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitor and an agent that increases motor neuron survival (SMN) protein expression. Furthermore, provided herein is a composition, a pharmaceutical formulation, or a kit comprising a 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitor and an agent that increases the expression of a motor neuron survival (SMN) protein.

The utility model discloses a nursing device for preventing muscle atrophy of a bedridden patient. The nursing device comprises a supporting assembly and a nursing assembly movably connected to the supporting assembly. When the nursing bed is used, the supporting assembly is connected with a bed body, meanwhile, the to-be-nursed part of a patient is located on the nursing assembly, and the position and angle of the to-be-nursed part of the patient are adjusted by moving and / or rotating the nursing assembly relative to the supporting assembly. When the nursing bed is used, the position and the angle of the nursing assembly are adjusted by moving and / or rotating the nursing assembly relative to the supporting assembly, the use comfort of a patient in the nursing process is improved, and the recovery progress of the bedridden patient is promoted.

This disclosure pertains to methods of treating or preventing spinal and bulbar muscular atrophy (SBMA), or one or more symptoms of SBMA, wherein the method comprises administering to a subject in need thereof an effective amount of Compound A, or a pharmaceutically acceptable salt thereof.

This disclosure provides a secretion centric therapy to overcome muscle wasting. Provided are mesenchymal stem cell secretion-based therapies to overcome muscle wasting due to: old age; as a consequence of immobilization (e.g., mobility restricted or paralytics administered); due to use of ventilators (e.g., in an ICU or long-term immobilization); in microgravity during long space flights; or, resulting from drug side effects (e.g., the use of weight loss drugs, chemotherapies, etc.). Uris disclosure further provides methods and compositions for modulating, including regulating or altering, the structure and function of diaphragm muscle cells and / or diaphragm muscle fibers in particular, and skeletal muscle in general. In certain embodiments extracellular vesicles are applied to patients affected by muscle wasting.

The present application relates to the microRNA drug technical field, specifically to the application of hsa-let-7f-5p in the preparation of a drug for treating muscle steatosis, and discloses that hsa-let-7f-5p can inhibit muscle fat infiltration by inhibiting fibroblast / adipogenic progenitor cell adipogenic differentiation, and hsa-let-7f-5p can be used as a microRNA drug in the treatment of diseases such as muscle fat infiltration and muscle steatosis, and diseases related to fat infiltration, for example, muscle atrophy, muscle injury, obesity, diabetes, etc. The relevant nucleic acid fragments are wrapped in liposomes, so that the drug stability and drug efficiency can be improved. The technical scheme can solve the technical problem that there is no drug capable of effectively inhibiting muscle steatosis and treating muscle injury in the prior art, and has an ideal application and promotion prospect in the fields of sports medicine and rehabilitation treatment.

The present invention relates to a composition for strengthening muscle strength or preventing, ameliorating or treating muscle loss, comprising a Lilium lancifolium extract as an active ingredient. Specifically, when C2C12 cells were pre-treated with a Lilium lancifolium extract, and then treated with H2O2, dexamethasone, or TNF-α, muscle damage was alleviated and muscle loss was inhibited, and the muscle mass and grip strength decreased by dexamethasone administration in a muscle atrophy mouse model were increased upon administration of the Lilium lancifolium extract. Therefore, the composition can be effectively used as a health functional food, medicine or feed additive for strengthening muscle strength or preventing, ameliorating or treating muscle loss.